Validation Data Gallery
Tested Applications
Recommended dilution
| Application | Dilution |
|---|---|
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Product Information
87497-1-PBS targets CD300f in WB, IHC, Indirect ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Recombinant |
| Type | Antibody |
| Immunogen |
CatNo: Eg10440 Product name: Recombinant human CD300F protein Source: mammalian cells-derived, pHZ-KIsec-C-6*HIS Tag: C-6*HIS Sequence: \ 相同性解析による交差性が予測される生物種 |
| Full Name | CD300 molecule-like family member f |
| Observed molecular weight | 40-60 kDa |
| Gene Symbol | CD300LF |
| Gene ID (NCBI) | 146722 |
| Conjugate | Unconjugated |
| Form | |
| Form | Liquid |
| Purification Method | Protein A purification |
| UNIPROT ID | Q8TDQ1 |
| Storage Buffer | PBS only{{ptg:BufferTemp}}7.3 |
| Storage Conditions | Store at -80°C. |
Background Information
CD300f (also known as CLM-1 or IREM-1) is a type I transmembrane glycoprotein belonging to the CD300 family of immunoreceptors. Expressed predominantly on myeloid cells, including macrophages, dendritic cells, and mast cells, CD300f functions as an inhibitory receptor that regulates immune responses. Its extracellular domain contains a single IgV-like domain that recognizes phosphatidylserine and phosphatidylethanolamine, enabling recognition of apoptotic cells. The cytoplasmic tail harbors immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that recruit phosphatases SHP-1 and SHP-2 upon phosphorylation, delivering negative signals. CD300f plays critical roles in dampening inflammation, promoting efferocytosis, and maintaining immune homeostasis (PMID: 28073916, PMID: 33548578, PMID: 37302321). The predicted molecular weight of CD300f is 32 kDa; however, due to different levels of N- and/or O-linked glycosylation modifications, its molecular weight may range from 40 to 60 kDa (PMID: 15549731, PMID: 31338922).



